PeptiMed, Inc. is a biotechnology company founded with the core mission of developing innovative therapeutic drugs targeting advanced cancers. Their flagship product, siEVI1, is a small interfering RNA (siRNA) drug designed to target the EVI1 gene, which is implicated in various cancers including breast, prostate, lung, colon, ovarian, and skin cancers. PeptiMed aims to provide effective treatment options for these severe conditions, focusing on the U.S. market.
Notable figures associated with PeptiMed include leading scientists and biotech investors who have supported the company's research and development efforts. Key achievements include significant progress in preclinical trials and securing funding to advance their therapeutic solutions. PeptiMed's impact lies in its potential to revolutionize cancer treatment by offering targeted, gene-specific therapies that could improve patient outcomes and quality of life.
